DE60326567D1 - Diagnose von hepatozellulärem karzinom - Google Patents
Diagnose von hepatozellulärem karzinomInfo
- Publication number
- DE60326567D1 DE60326567D1 DE60326567T DE60326567T DE60326567D1 DE 60326567 D1 DE60326567 D1 DE 60326567D1 DE 60326567 T DE60326567 T DE 60326567T DE 60326567 T DE60326567 T DE 60326567T DE 60326567 D1 DE60326567 D1 DE 60326567D1
- Authority
- DE
- Germany
- Prior art keywords
- hepatocellular carcinoma
- diagnosis
- gpc3
- subject
- glypican
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38234002P | 2002-05-23 | 2002-05-23 | |
PCT/CA2003/000752 WO2003100429A2 (en) | 2002-05-23 | 2003-05-22 | Diagnosis of hepatocellular carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60326567D1 true DE60326567D1 (de) | 2009-04-23 |
Family
ID=29584393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60326567T Expired - Lifetime DE60326567D1 (de) | 2002-05-23 | 2003-05-22 | Diagnose von hepatozellulärem karzinom |
Country Status (18)
Country | Link |
---|---|
US (1) | US7883853B2 (de) |
EP (1) | EP1506406B1 (de) |
JP (1) | JP4455324B2 (de) |
CN (1) | CN100401068C (de) |
AT (1) | ATE425461T1 (de) |
AU (1) | AU2003229191B2 (de) |
BR (1) | BRPI0311233B8 (de) |
CA (1) | CA2482881C (de) |
DE (1) | DE60326567D1 (de) |
ES (1) | ES2324029T3 (de) |
HK (1) | HK1074251A1 (de) |
IL (1) | IL164848A0 (de) |
MX (1) | MXPA04011132A (de) |
NZ (1) | NZ536521A (de) |
PT (1) | PT1506406E (de) |
RU (1) | RU2319969C2 (de) |
WO (1) | WO2003100429A2 (de) |
ZA (1) | ZA200410077B (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002338020A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
AU2002328429A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
WO2004023145A1 (ja) * | 2002-09-04 | 2004-03-18 | Perseus Proteomics Inc. | Gpc3の検出による癌の診断方法 |
WO2004067571A1 (fr) * | 2003-01-30 | 2004-08-12 | Wu, Mengchao | Anticorps monoclonal contre l'hepatome humain et utilisation de celui-ci |
US20080008710A1 (en) * | 2003-09-04 | 2008-01-10 | Hiroyuki Aburatani | Therapeutic Agent And Diagnostic Agent For Cholangiocarcinoma |
WO2005085861A2 (en) * | 2004-03-03 | 2005-09-15 | Oridis Biomed Forschungs- Und Entwicklungs Gmbh | Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer |
US7691586B2 (en) | 2004-04-28 | 2010-04-06 | Perseus Proteomics Inc. | Method for predicting and judging the recurrence of liver cancer after treating liver cancer |
ATE486610T1 (de) * | 2004-07-09 | 2010-11-15 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3-antikörper |
EP1800693B1 (de) * | 2004-08-24 | 2013-07-17 | Chugai Seiyaku Kabushiki Kaisha | Adjuvante therapie mit verwendung von anti-glypican-3-antikörper |
US20080003623A1 (en) * | 2004-10-05 | 2008-01-03 | Atsushi Nakajima | Monitoring Agent for Seriousness of Hepatitis |
TWI468514B (zh) | 2004-10-26 | 2015-01-11 | Chugai Pharmaceutical Co Ltd | Sugar chain modified phosphatidylinositol glyphosyl 3 antibody |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
WO2007053659A2 (en) * | 2005-11-01 | 2007-05-10 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of screening for hepatocellular carcinoma |
TW200949248A (en) * | 2008-03-17 | 2009-12-01 | Univ Miyazaki | Method for detection of liver cancer cell using anti-glypican-3 antibody |
CN101393217B (zh) * | 2008-09-27 | 2012-05-30 | 中国人民解放军第二军医大学 | 一种原发性肝癌血清标志物的检测试剂盒 |
WO2010048304A2 (en) * | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
WO2010098613A2 (ko) * | 2009-02-27 | 2010-09-02 | 포항공과대학교 산학협력단 | Tm7sf3를 유효성분으로 함유하는 간암 진단용 조성물, 및 항 tm7sf3 항체를 유효성분으로 함유하는 간암 진단 키트, 및 간암 예방 또는 치료용 약학 조성물 |
WO2010100862A1 (ja) | 2009-03-05 | 2010-09-10 | 独立行政法人産業技術総合研究所 | 肝内胆管がんの検出、判別方法 |
CN102180969B (zh) * | 2011-01-30 | 2013-04-10 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗肝癌活性单克隆抗体及其应用 |
CN102183660A (zh) * | 2011-03-09 | 2011-09-14 | 倪温慨 | 检测Glypican-3的时间分辨免疫荧光试剂盒 |
CN102353791A (zh) * | 2011-06-30 | 2012-02-15 | 倪润洲 | 一种分离检测afp亚型的新方法 |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
EP3557260B1 (de) | 2012-12-21 | 2022-05-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-gerichtetes arzneimittel, das einem patienten verabreicht wird, der auf die gpc3-gerichtete arzneimitteltherapie reagiert |
US20160000946A1 (en) * | 2013-03-14 | 2016-01-07 | The Board Of Trustees Of The Leland Stanford Junior University | Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma |
WO2015020242A1 (ko) * | 2013-08-06 | 2015-02-12 | Kim Hyun Kee | 소 간세포암 및 간경변에 잠재되어 있는 간세포암 진단용 조성물 |
CN105849562B (zh) | 2013-12-24 | 2019-08-16 | 中外制药株式会社 | 可溶性gpc3蛋白质的测定方法 |
SG11201609014TA (en) | 2014-05-08 | 2016-12-29 | Chugai Pharmaceutical Co Ltd | Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
MX2016015162A (es) * | 2014-05-22 | 2017-03-03 | Genentech Inc | Anticuerpos anti - gpc3 e inmunoconjugados. |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
KR101704533B1 (ko) * | 2014-10-13 | 2017-02-09 | 경북대학교병원 | 간암 바이오마커로서의 ERRγ 및 이의 용도 |
WO2017002934A1 (ja) | 2015-07-01 | 2017-01-05 | 中外製薬株式会社 | Gpc3標的治療剤が有効である患者に投与されるgpc3標的治療剤 |
CN106397593B (zh) * | 2015-08-03 | 2019-09-10 | 科济生物医药(上海)有限公司 | 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用 |
EP3428648B1 (de) * | 2016-03-10 | 2020-12-02 | National Cancer Center | Verfahren zur unterstützung der vorhersage des rezidivrisikos bei einem patienten mit hepatozellulärem karzinom, und verwendung eines kits |
TW202248213A (zh) | 2016-03-15 | 2022-12-16 | 日商中外製藥股份有限公司 | 使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法 |
EP3684413A1 (de) | 2017-09-20 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Dosierungsschema für kombinationstherapie unter verwendung von pd-1-achse-bindenden antagonisten und gegen gpc3 gerichteten wirkstoff |
WO2023091909A1 (en) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171850A (en) * | 1988-08-31 | 1992-12-15 | The Ontario Cancer Institute | Intestinal oncofetal gene |
JP2946216B2 (ja) | 1989-07-12 | 1999-09-06 | 武田薬品工業株式会社 | 新規ハイブリドーマ,モノクローナル抗体および用途 |
EP0477739A3 (en) * | 1990-09-27 | 1992-12-09 | F. Hoffmann-La Roche Ag | Glycosyl-phosphatidylinositol-specific phospholipase d |
WO1999037764A2 (en) | 1998-01-27 | 1999-07-29 | Vlaams Interuniversitair Instituut Voor Biotechnologie | New members of the glypican gene family |
EP1146903A4 (de) * | 1998-10-16 | 2005-02-16 | Univ California | Glypicane zur detektion und behandlung humaner karzinome |
ATE407204T1 (de) * | 2001-06-22 | 2008-09-15 | Chugai Pharmaceutical Co Ltd | Zellproliferationsinhibitoren mit anti-glypican-3-antikörper |
-
2003
- 2003-05-22 CA CA2482881A patent/CA2482881C/en not_active Expired - Lifetime
- 2003-05-22 AU AU2003229191A patent/AU2003229191B2/en not_active Expired
- 2003-05-22 ES ES03724724T patent/ES2324029T3/es not_active Expired - Lifetime
- 2003-05-22 PT PT03724724T patent/PT1506406E/pt unknown
- 2003-05-22 IL IL16484803A patent/IL164848A0/xx not_active IP Right Cessation
- 2003-05-22 DE DE60326567T patent/DE60326567D1/de not_active Expired - Lifetime
- 2003-05-22 JP JP2004507835A patent/JP4455324B2/ja not_active Expired - Lifetime
- 2003-05-22 WO PCT/CA2003/000752 patent/WO2003100429A2/en active Application Filing
- 2003-05-22 NZ NZ536521A patent/NZ536521A/en not_active IP Right Cessation
- 2003-05-22 EP EP03724724A patent/EP1506406B1/de not_active Revoked
- 2003-05-22 BR BRPI0311233A patent/BRPI0311233B8/pt not_active IP Right Cessation
- 2003-05-22 RU RU2004136285/15A patent/RU2319969C2/ru active
- 2003-05-22 AT AT03724724T patent/ATE425461T1/de not_active IP Right Cessation
- 2003-05-22 CN CNB038107910A patent/CN100401068C/zh not_active Expired - Lifetime
- 2003-05-22 US US10/514,294 patent/US7883853B2/en not_active Expired - Lifetime
- 2003-05-22 MX MXPA04011132A patent/MXPA04011132A/es active IP Right Grant
-
2004
- 2004-12-14 ZA ZA2004/10077A patent/ZA200410077B/en unknown
-
2005
- 2005-08-04 HK HK05106720.9A patent/HK1074251A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ536521A (en) | 2006-04-28 |
AU2003229191B2 (en) | 2009-07-30 |
ES2324029T3 (es) | 2009-07-29 |
IL164848A0 (en) | 2005-12-18 |
WO2003100429A2 (en) | 2003-12-04 |
WO2003100429A3 (en) | 2004-02-19 |
ATE425461T1 (de) | 2009-03-15 |
PT1506406E (pt) | 2009-06-03 |
CN100401068C (zh) | 2008-07-09 |
JP2005526979A (ja) | 2005-09-08 |
BRPI0311233B8 (pt) | 2021-07-27 |
AU2003229191A1 (en) | 2003-12-12 |
RU2004136285A (ru) | 2005-10-10 |
EP1506406B1 (de) | 2009-03-11 |
JP4455324B2 (ja) | 2010-04-21 |
US7883853B2 (en) | 2011-02-08 |
ZA200410077B (en) | 2005-12-28 |
BRPI0311233A2 (pt) | 2016-06-28 |
RU2319969C2 (ru) | 2008-03-20 |
BRPI0311233B1 (pt) | 2019-08-13 |
CA2482881A1 (en) | 2003-12-04 |
HK1074251A1 (en) | 2005-11-04 |
CN1653336A (zh) | 2005-08-10 |
EP1506406A2 (de) | 2005-02-16 |
CA2482881C (en) | 2016-11-08 |
MXPA04011132A (es) | 2005-08-15 |
US20050233392A1 (en) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60326567D1 (de) | Diagnose von hepatozellulärem karzinom | |
GB0510943D0 (en) | Improved immunoassay methods | |
ATE365922T1 (de) | Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) | |
CA2623653A1 (en) | Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis | |
WO2010011357A3 (en) | Detection of prostate cancer using psa glycosylation patterns | |
MXPA06012232A (es) | Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas. | |
ATE370414T1 (de) | Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs | |
ATE447713T1 (de) | S100-proteine und -autoantikörper als serummarker für krebs | |
DE60325382D1 (de) | Verfahren zur diagnose von gebärmutterhalskrebs | |
NO20062280L (no) | Test | |
SE0602683L (sv) | Diagnostisk metod | |
DE602004017317D1 (de) | Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome | |
DE602005010548D1 (de) | Verbessertes verfahren zur diagnose des akuten koronarsyndroms | |
DK1095271T3 (da) | Fremgangsmåde til diagnose af hjertekar-sygdomme og tidlig aterosklerose | |
DE602004026869D1 (de) | Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers | |
ATE509270T1 (de) | Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung | |
ATE394675T1 (de) | Verfahren zum nachweis von brustkrebs | |
DE602004013554D1 (de) | Verbindungen und verfahren zur diagnose von prostatakrebs | |
DE60229513D1 (de) | Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten | |
DE602004001994D1 (de) | Verwendung des proteins masp als marker für kolorektale karzinome | |
JP5133842B2 (ja) | 癌が疑われる患者または癌患者由来の組織の癌部と非癌部との判別方法およびそれに用いる判別試薬 | |
DE602004013355D1 (de) | Verwendung des proteins spee als marker für brustkrebs | |
Toyoda et al. | Postinterferon α-fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: cause or results? | |
ATE337554T1 (de) | Verfaren zur diagnose von neoplasmen | |
ATE483163T1 (de) | Verfahren zur diagnose von tumoren durch messung des niveaus von apolipoprotein a-iv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: SUNNYBROOK HEALTH SCIENCES CENTRE, TORONTO, ON, CA |